Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - RuiYi

  • RuiYi Licenses mAb Development to China's Genor
    RuiYi said today that it will co-develop its monoclonal antibody RYI-008 in China with a ... The agreement comes just two days after RuiYi announced it would accelerate development of ...
    5-16-2013
  • RuiYi, CMC Collaborate to Speed mAb Development
    RuiYi is developing RYI-008 under a global commercialization license from Belgian-owned ... Under an agreement announced in October, RuiYi agreed to take over development of the ...
    5-14-2013
  • Shire Rare-Disease Partnerships Expand
    arGEN-X made progress with another commercial partner last October, when it granted RuiYi (formerly Anaphore) a worldwide exclusive license to develop and commercialize ...
    1-7-2013
  • Top 20 Venture Capital Firms
    ... PhaseRx, Quanticel Pharmaceuticals, RuiYi, Semprae Laboratories, Spark Diagnostics, Theraclone Sciences, Transcept Pharmaceuticals, Veracyte, Viral Logic Systems Technology (VLST). ...
    12-17-2012
  • RuiYi Nabs Rights to arGEN-X IL-6 mAb
    RuiYi (formerly Anaphore) negotiated a worldwide exclusive license to ArGEN-X' preclinical ... Under terms of the deal, RuiYi will make arGEN-X an up-front cash fee and equity ...
    10-4-2012

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll